Advanced hybrid closed loop (AHCL), sometimes referred to as artificial pancreas or automated insulin delivery (AID), is currently the most advanced commercial insulin delivery technology for T1D, having evolved from early sensor augmented pump (SAP) therapy, and then hybrid closed loop [5, 6]. Here, INS is linked to type 1 diabetes mellitus.